BCB-214

About BrainChild Bio

BrainChild Bio is a private, clinical-stage biotech based in San Diego, founded in 2018, developing next-generation CAR-T therapies for CNS tumors. The company's core innovation is a platform for repetitive, direct cerebroventricular delivery of engineered T-cells via an implantable shunt, combined with synthetic biology modules for multiplexed targeting, potency enhancement, and conditional control. With a pivotal trial planned for its lead pediatric program in DIPG and a pipeline targeting broader CNS oncology, BrainChild Bio aims to address significant unmet needs in both pediatric and adult neuro-oncology.

Therapeutic Areas

Other CNS Tumors (unspecified) Drugs